Donald Santel

Donald Santel is an accomplished biotechnology and medical device executive with extensive leadership experience in various roles. Currently serving as an Independent Director at Aerovate Therapeutics, Inc., Donald also holds positions as Chairman of the Board at Tentarix Biotherapeutics and Ocelot Bio. Previously, Donald was Chairperson of the Board at Oyster Point Pharma until its acquisition by Viatris. Donald's experience includes serving as Executive Chairman, Interim CEO, and Independent Director at Adicet Bio, and President & CEO at Hyperion Therapeutics, where responsibilities encompassed overseeing all company operations from development through commercialization. Notably, Donald has successfully raised significant capital throughout career, including $118 million in private funding and $114 million as a public company, demonstrating a strong track record in biotech entrepreneurship. Donald's educational background includes a Master of Science in Electrical and Electronics Engineering from the University of Minnesota and a Bachelor of Science in Biomedical Engineering from Purdue University.